AR002012A1 - Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. - Google Patents

Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.

Info

Publication number
AR002012A1
AR002012A1 ARP950100660A AR10066095A AR002012A1 AR 002012 A1 AR002012 A1 AR 002012A1 AR P950100660 A ARP950100660 A AR P950100660A AR 10066095 A AR10066095 A AR 10066095A AR 002012 A1 AR002012 A1 AR 002012A1
Authority
AR
Argentina
Prior art keywords
compound
understands
preparation
pharmaceutical composition
therapeutic treatment
Prior art date
Application number
ARP950100660A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426020.5A external-priority patent/GB9426020D0/en
Priority claimed from GBGB9426030.4A external-priority patent/GB9426030D0/en
Priority claimed from GBGB9511600.0A external-priority patent/GB9511600D0/en
Priority claimed from GBGB9511599.4A external-priority patent/GB9511599D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR002012A1 publication Critical patent/AR002012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de fórmula (I), en la cual R1 y R2, los cuales pueden ser los mismos o diferentes, está cada uno seleccionado de hidrógeno, halógeno, oC(1-8)alquil; R3 es aril o C(1-4)alquil el cual puede ser opcionalmente sustituido; X es un grupo de ligazón o unión; Y es un grupo aril opcionalmentesustituido; y n es 0, 1 ó 2. Son inhibidores de la enzima LpPLA2 y del mismo en uso y tratamiento de arteriosclerosis.
ARP950100660A 1994-12-22 1995-12-20 Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. AR002012A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9426020.5A GB9426020D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9426030.4A GB9426030D0 (en) 1994-12-23 1994-12-23 Novel compounds
GBGB9511600.0A GB9511600D0 (en) 1995-06-08 1995-06-08 Novel compounds
GBGB9511599.4A GB9511599D0 (en) 1995-06-08 1995-06-08 Novel compounds

Publications (1)

Publication Number Publication Date
AR002012A1 true AR002012A1 (es) 1998-01-07

Family

ID=27451242

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100660A AR002012A1 (es) 1994-12-22 1995-12-20 Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.

Country Status (24)

Country Link
US (1) US5990102A (es)
EP (1) EP0799200A1 (es)
JP (1) JPH11500415A (es)
CN (1) CN1175246A (es)
AP (1) AP9701007A0 (es)
AR (1) AR002012A1 (es)
AU (1) AU704407B2 (es)
BG (1) BG101687A (es)
BR (1) BR9510420A (es)
CA (1) CA2208530A1 (es)
CZ (1) CZ192297A3 (es)
DZ (1) DZ1958A1 (es)
FI (1) FI972584L (es)
HU (1) HUT77089A (es)
IL (1) IL116485A0 (es)
MA (1) MA23834A1 (es)
MX (1) MX9704736A (es)
NO (1) NO972909L (es)
NZ (1) NZ298416A (es)
OA (1) OA10737A (es)
PL (1) PL320937A1 (es)
SK (1) SK80397A3 (es)
TR (1) TR199501655A2 (es)
WO (1) WO1996019451A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU708032B2 (en) * 1995-07-01 1999-07-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
NZ332476A (en) * 1996-04-26 2000-06-23 Smithkline Beecham Plc substituted 4-(carboxybenzylsulphinyl)-2-oxo-azetidine derivatives
WO2000005204A1 (en) * 1998-07-23 2000-02-03 Shionogi & Co., Ltd. MONOCYCLIC β-LACTAM COMPOUNDS AND CHYMASE INHIBITORS CONTAINING THE SAME
SI1686119T1 (sl) 2000-02-16 2009-12-31 Smithkline Beecham Plc Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
EP1747014A4 (en) * 2004-05-03 2007-09-12 Ilypsa Inc MODULATION OF LYSOPHOSPHATIDYLCHOLINE AND TREATMENT OF CONDITIONS INDUCED BY A DIET
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
ES2540933T3 (es) 2007-05-11 2015-07-14 Thomas Jefferson University Métodos de tratamiento y prevención de enfermedades y trastornos neurodegenerativos
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
EP2725024A4 (en) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica HETEROCYCLIC AZOL COMPOUND, METHOD OF MANUFACTURING THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CA2842965A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
JP2014521625A (ja) 2011-07-27 2014-08-28 グラクソ グループ リミテッド 二環式ピリミドン化合物
BR112015017397A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos pirimidona bicíclica como inibidores de lp-pla2
KR20150111356A (ko) 2013-01-25 2015-10-05 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
JP6306053B2 (ja) 2013-01-25 2018-04-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤
WO2015179293A1 (en) * 2014-05-18 2015-11-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule activators and inhibitors of lecithin: cholesterol acyltransferase
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
EP4056571A4 (en) 2019-11-09 2024-01-24 Shanghai Simr Biotechnology Co., Ltd. Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途
WO2025015951A1 (zh) 2023-07-17 2025-01-23 上海枢境生物科技有限公司 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5559193A (en) * 1978-09-20 1980-05-02 Glaxo Group Ltd Bblactam compound
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI972584A7 (fi) 1997-08-19
BG101687A (bg) 1998-02-27
BR9510420A (pt) 2004-04-20
FI972584L (fi) 1997-08-19
NO972909D0 (no) 1997-06-20
DZ1958A1 (fr) 2002-02-17
TR199501655A2 (tr) 1996-07-21
AU4389896A (en) 1996-07-10
CN1175246A (zh) 1998-03-04
NO972909L (no) 1997-08-20
OA10737A (en) 2002-12-10
AU704407B2 (en) 1999-04-22
HUT77089A (hu) 1998-03-02
EP0799200A1 (en) 1997-10-08
CA2208530A1 (en) 1996-06-27
MX9704736A (es) 1997-10-31
CZ192297A3 (en) 1997-11-12
PL320937A1 (en) 1997-11-10
NZ298416A (en) 1999-03-29
MA23834A1 (fr) 1996-10-01
FI972584A0 (fi) 1997-06-17
US5990102A (en) 1999-11-23
AP9701007A0 (en) 1997-07-31
JPH11500415A (ja) 1999-01-12
WO1996019451A1 (en) 1996-06-27
SK80397A3 (en) 1998-01-14
IL116485A0 (en) 1996-08-04

Similar Documents

Publication Publication Date Title
AR002012A1 (es) Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto.
MX9301986A (es) Derivados de perhidroisoindol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CL2003002756A1 (es) Compuestos derivados de (1-carbamoil-1,1-defenilmetil)-1-[substituido)alquil]purrolidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sindrome de intestino irritable o incontinencia.
ES2056190T3 (es) Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa.
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
NO964236D0 (no) Anvendelse av serotonin-antagonister (5HT3) for behandling av fibromyalgi
UY24555A1 (es) Nuevos compuestos
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
AR034897A1 (es) Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
BR9807674A (pt) Inibidores bicìclicos da proteìna farnesil transferase
ES2058292T3 (es) Derivados de indol.
AR024138A1 (es) Inhibidores de la proliferacion celular
NO902301L (no) Fremgangsmaate for fremstilling av diarylstyrylkinolin-disyrer.
DK0471756T3 (da) Saccharinderivater, der er egnede som proteolytiske enzyminhibitorer, og fremstilling deraf
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
ATE384722T1 (de) Alkoxypyridinderivate
NO165921C (no) Fremgangsmaate for fremstilling av disubstituerte prolinderivater.
ATE94409T1 (de) Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
NO991230L (no) Trisykliske forbindelser for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
EA200000522A1 (ru) 5-htагонисты